Company Profile

Phenex Pharmaceuticals AG was founded in 2002. It is a privately held drug discovery & development company based in the Biotech Cluster Rhine-Neckar with Biology and Chemistry laboratories and offices primarily in Heidelberg and partly in Ludwigshafen.

Our company focuses its small-molecule drug discovery expertise in Liver and Gastrointestinal disease areas and has now recently entered the field of Cancer Therapy.

We not only devise novel therapeutics for known targets but additionally aim to identify novel molecular mechanisms. This provides the basis for the identification of novel small molecules with "game changing" capabilities.

Historically, Phenex has identified two of such novel mechanisms from literature and has translated them into proprietary novel therapeutic small molecules.

The first program being RORγt inverse agonists in inflammation and autoimmune diseases - which is partnered since late 2012 with Janssen Biotech in a deal valued at 135 M USD.

The second was the FXR program, geared towards a drug to treat Non-Alcoholic Steatohepatitis (NASH), Primary Biliary Cholangitis (PBC) and other severe liver diseases - this was acquired by Gilead Sciences in late 2014 in a 465 M USD deal.

Since, both companies - Janssen and Gilead, have progressed with our development candidates into the clinic, Phenex can expect further milestone payments in the next few years.

These financial resources and our expertise have helped Phenex significantly advance not only in liver and gastrointestinal metabolism but additionally venture into up-coming fields of cancer immune and cancer metabolism based therapy.

Learn more about our 'R&D programs'